切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2019, Vol. 07 ›› Issue (01) : 75 -80. doi: 10.3877/cma.j.issn.2095-5782.2019.01.015

所属专题: 文献

综述

射频消融联合其他介入综合技术治疗原发性肝癌研究进展
陈丽1, 应希慧1, 涂建飞1, 张登科1, 吴发宗1, 纪建松1,()   
  1. 1. 323000 丽水,浙江大学医学院丽水医院,丽水市中心医院影像诊断与介入微创中心
  • 收稿日期:2018-12-03 出版日期:2019-02-01
  • 通信作者: 纪建松
  • 基金资助:
    浙江省基础公益研究计划(LGF18H220001); 浙江省医药卫生科技计划项目面上项目(201825360); 丽水市医学重点学科建设项目(2017ZDXK05)

Research progress on radiofrequency ablation combined with other interventional techniques for treatment of primary liver cancer

Li Chen1, Xihui Ying1, Jianfei Tu1, Dengke Zhang1, Fazong Wu1, Jiansong Ji1,()   

  1. 1. Department of Radiology, Lishui Central Hospital, Lishui Hospital, School of Medicine, Zhejiang University, Lishui 323000, China
  • Received:2018-12-03 Published:2019-02-01
  • Corresponding author: Jiansong Ji
  • About author:
    Corresponding author: Ji Jiansong, Email:
引用本文:

陈丽, 应希慧, 涂建飞, 张登科, 吴发宗, 纪建松. 射频消融联合其他介入综合技术治疗原发性肝癌研究进展[J/OL]. 中华介入放射学电子杂志, 2019, 07(01): 75-80.

Li Chen, Xihui Ying, Jianfei Tu, Dengke Zhang, Fazong Wu, Jiansong Ji. Research progress on radiofrequency ablation combined with other interventional techniques for treatment of primary liver cancer[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(01): 75-80.

原发性肝癌(HCC)死亡率居全球第三位,而中国肝癌患者的年发病及死亡病例数均超过全球总数的50%。目前,手术仍是唯一有可能治愈HCC的首选方法,但绝大多数患者发现时已为肝癌中晚期,失去了手术机会。近年来介入微创治疗已成为不可手术切除肝癌治疗的研究热点之一,主要包括:肝动脉化疗栓塞(TACE)、局部消融治疗、放射性粒子组织间近距离放疗及体外高能聚焦超声波等。由于介入微创治疗方式多样,如何合理有序的联合应用仍是当前的研究热点。本文重点综述以射频消融为基础的各种介入综合技术手段联合应用治疗肝癌的新进展。

The mortality rate of primary liver cancer (HCC) ranks third in the world, while the annual incidence and mortality of hepatocellular carcinoma patients in China are more than 50% of the global average. At present, surgery is still the only method that may cure HCC, but the majority of patients have no chance of surgery when found to be in the advanced stage. In recent years, interventional minimally invasive treatment has become one of the hotspots for the treatment of unresectable liver cancer, including transcatheter arterial chemoembolization (TACE) , local ablation therapy, brachytherapy between radioactive particles, and high-intensity focused ultrasound in vitro. Due to the variety of interventional minimally invasive treatment methods, how to use rational and orderly joint application is still the current research hotspot. This article mainly focuses on the new advances in the application of various interventional integrated techniques based on radiofrequency ablation for the treatment of liver cancer.

[1]
Torre L A, Bray F, Siegel RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[2]
Chen W, Zheng R, Baade PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[3]
Chen K, Chen G, Wang H,et al. Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: a prospective randomized controlled trial[J]. J Hepatol,2014,61(6):1304-1311.
[4]
Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours[J]. Cardiovasc Intervent Radiol,2010,33(1):11-17.
[5]
Lee MW. Comments on "Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?"[J]. Radiology,2010,254(2):633; author reply 634.
[6]
European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol,2012,56(4):908-943.
[7]
Seror O, N'Kontchou G, Ibraheem M,et al. Large(>or=5.0-cm)HCCs: multipolar RF ablation with three internally cooled bipolar electrodes-initial experience in 26 patients[J]. Radiology,2008,248(1):288-296.
[8]
Tateishi R, Shiina S, Akahane M,et al. Frequency,risk factors and survival associated with an intrasubsegmental recurrence after radiofrequency ablation for hepatocellular carcinoma[J]. PLoS ONE,2013,8(4):e59040.
[9]
Peng ZW, Zhang YJ, Chen MS,et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial[J]. J Clin Oncol,2013,31(4):426-432.
[10]
Dohmen K, Shirahama M, Shigematsu H,et al. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate[J]. Hepatogastroenterology,2001,48(41):1409-1415.
[11]
Kim JH, Won HJ, Shin YM,et al. Medium-sized(3.1-5.0 cm)hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone[J]. Ann Surg Oncol,2011,18(6):1624-1629.
[12]
Morimoto M, Numata K, Kondou M,et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J]. Cancer,2010,116(23):5452-5460.
[13]
Ji J, Gao J, Zhao L,et al. Computed tomography-guided radiofrequency ablation following transcatheter arterial embolization in treatment of large hepatic hemangiomas[J]. Medicine(Baltimore),2016,95(15):e3402.
[14]
Ji J, Gao J, Zhao L,et al. Computed Tomography-Guided Radiofrequency Ablation Following Transcatheter Arterial Embolization in Treatment of Large Hepatic Hemangiomas[J]. Medicine,2016,95(15):e3402.
[15]
Guo YJ, Huang WS, Zhou B et al. Transarterial chemoembolization plus computed tomography-guided percutaneous radiofrequency ablation for small hepatocellular carcinoma in special locations[J]. Zhonghua Yi Xue Za Zhi,2013,93(33):2627-2630.
[16]
Toshimori J, Nouso K, Nakamura S,et al. Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location[J]. Acta Med Okayama,2015,69(4):219-226.
[17]
Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status[J]. Cancer Lett,2016,370(1):78-84.
[18]
Sakr AA, Saleh AA, Moeaty AA,et al. The combined effect of radiofrequency and ethanol ablation in the management of large hepatocellular carcinoma[J]. Eur J Radiol,2005,54(3):418-425.
[19]
Li Z, Zhang K, Lin SM,et al. Radiofrequency ablation combined with percutaneous ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Int J Hyperthermia,2016:1-10.
[20]
Zhu ZX, Liao MH, Wang XX,et al. Radiofrequency ablation with or without ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Minerva Med,2016,107(6):381-391.
[21]
Wong SN, Lin CJ, Lin CC,et al. Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations[J]. AJR Am J Roentgenol,2008,190(3):W187-W195.
[22]
Kurokohchi K, Watanabe S, Masaki T,et al. Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma[J]. World J Gastroenterol,2005,11(10):1426-1432.
[23]
Kurokohchi K, Masaki T, Watanabe S,et al. Time-lag performance of radiofrequency ablation after percutaneous ethanol injection for the treatment of hepatocellular carcinoma[J]. Int J Oncol,2006,28(4):971-976.
[24]
Shrimal A, Prasanth M, Kulkarni AV. Interventional radiological treatment of hepatocellular carcinoma: an update[J]. Indian J Surg,2012,74(1):91-99.
[25]
Boerman OC, Koppe MJ, Postema EJ,et al. Radionuclide therapy of cancer with radiolabeled antibodies[J]. Anticancer Agents Med Chem,2007,7(3):335-343.
[26]
Tu J, Ji J, Wu F,et al. Effectiveness of combined(131)I-chTNT and radiofrequency ablation therapy in treating advanced hepatocellular carcinoma[J]. Cell Biochem Biophys,2015,71(2):777-784.
[27]
Rousse C, Chauvet B. Recommendations for inspections of the French nuclear safety authority[J]. Cancer Radiother,2015,19(6-7):634-637.
[28]
Zhongmin W, Yu L, Fenju L,et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer[J]. European Radiology,2010,20(7):1786-1791.
[29]
Li C, Zhang F, Zhang W,et al. Feasibility of(125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol,2010,136(11):1633-1640.
[30]
Peng S, Yang QX, Zhang T,et al. Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma[J]. Asian Pac J Cancer Prev,2014,15(13):5155-5160.
[31]
Tu JF, Xu HH, Ying XH,et al. Comparative study of several microinvasive treatments for large hepatocellular carcinoma[J]. Eur Rev Med Pharmacol Sci,2015,19(1):45-53.
[32]
Santambrogio R, Chiang J, Barabino M,et al. Comparison of Laparoscopic Microwave to Radiofrequency Ablation of Small Hepatocellular Carcinoma(≤3 cm)[J]. Ann Surg Oncol,2017,24(1):257-263.
[33]
Ginsburg M, Zivin SP, Wroblewski K,et al. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation[J]. J Vasc Interv Radiol,2015,26(3):330-341.
[34]
Vogl TJ, Farshid P, Naguib NN,et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation[J]. Abdom Imaging,2015,40(6):1829-1837.
[35]
Lencioni R, de Baere T, Martin RC,et al. Image-guided ablation of malignant liver tumors: Recommendations for clinical validation of novel thermal and non-thermal technologies-a western perspective[J]. Liver Cancer,2015,4(4):208-214.
[36]
de Baere T, Deschamps F. New tumor ablation techniques for cancer treatment(microwave,electroporation)[J]. Diagn Interv Imaging,2014,95(7-8):677-682.
[37]
Sheta E, El-Kalla F, El-Gharib M,et al. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: a randomized-controlled study[J]. Eur J Gastroenterol Hepatol,2016,28(10):1198-1203.
[38]
Lee KF, Wong J, Hui JW,et al. Long-term outcomes of microwave versus radiofrequency ablation for hepatocellular carcinoma by surgical approach: A retrospective comparative study[J]. Asian J Surg,2017,40(4):301-308.
[39]
Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis[J]. Int J Hyperthermia,2016,32(3):339-344.
[40]
Ierardi AM, Floridi C, Fontana F,et al. Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation[J]. Radiol Med,2013,118(6):949-961.
[41]
Correa-Gallego C, Fong Y, Gonen M,et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases[J]. Ann Surg Oncol,2014,21(13):4278-4283.
[42]
Zhou Y, Zhao Y, Li B,et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma[J]. BMC Gastroenterol,2010,10:78.
[43]
Choi D, Lim HK, Rhim H,et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series[J]. Eur Radiol,2007,17(3):684-692.
[44]
Choi D, Lim HK, Joh JW,et al. Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors[J]. Ann Surg Oncol,2007,14(12):3510-3518.
[45]
Choi D, Lim HK, Rhim H. Concurrent and subsequent radiofrequency ablation combined with hepatectomy for hepatocellular carcinomas[J]. World J Gastrointest Surg,2010,2(4):137-142.
[1] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[2] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径<1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[3] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[4] 林巧, 周丽. RFA联合LAH术治疗原发性肝癌并门静脉癌栓的临床效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 521-524.
[5] 曾繁利, 齐秩凯, 杨贺庆. 两种经Glisson蒂鞘解剖路径肝切除术治疗原发性肝癌的肿瘤学疗效及风险比对[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 525-527.
[6] 马立伟, 贾志强, 陈午盛, 邵明亮, 刘琼, 段玉松. CalliSpheres载药微球联合碘化油治疗肝癌的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 369-372.
[7] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[8] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[9] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[10] 鲍乐, 刘颖, 王友彬, 陈龙, 朱玉芝, 梁爽, 权鹤太, 李鹏飞. 还阳通络灸在原发性肝癌介入治疗中的临床应用研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(03): 197-202.
[11] 莫鹏, 郭杏春, 梁秀娟, 王耀明. 超声引导与CT引导射频消融治疗肝细胞癌患者疗效及预后比较[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 151-154.
[12] 广东省护士协会介入护士分会, 广东省医师协会介入医师分会. 原发性肝癌低血糖患者护理规范管理专家共识[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 709-714.
[13] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
[14] 陈轶维, 吴近近, 李奋, 孙彦隽, 郁夏风. 儿童左心耳起源房性心动过速镶嵌治疗一例[J/OL]. 中华心脏与心律电子杂志, 2024, 12(03): 185-188.
[15] 王楠钧, 马燕, 李隆松, 牛晓彤, 刘圣圳, 毕雅维, 苏松, 柴宁莉, 令狐恩强. 不同年龄段胃低级别上皮内瘤变患者内镜下射频消融术的疗效对比分析[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(04): 238-242.
阅读次数
全文


摘要